Anagram Therapeutics, Inc.
Alexey Margolin is a highly experienced pharmaceutical executive with a significant track record in leadership and innovation within the industry. Currently serving as the Chairman of the Board at Anagram Therapeutics, Inc., Alexey has held prominent roles such as Director and Co-Founder and CEO at Alcresta Therapeutics since September 2011. Previous leadership positions include Chairman of the Board at Synspira Therapeutics, Inc. from October 2020 to March 2023, and Chairman of the Board at Allena Pharmaceuticals, where Alexey also served as Co-Founder and CEO from September 2011 to January 2019. Additionally, Alexey was Co-Founder and CEO of Alnara Pharmaceuticals and held the role of Chief Scientific Officer at Altus Pharmaceuticals from 1993 to 2007. Alexey Margolin earned a Doctor of Philosophy in Chemistry from Lomonosov Moscow State University.
This person is not in the org chart
This person is not in any teams
Anagram Therapeutics, Inc.
Anagram is a clinical stage company leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can make a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. Malabsorption syndromes and nutrient metabolism disorders prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. ANG003, Anagram’s lead product is intended for the treatment of malabsorption and exocrine pancreatic insufficiency and is a new class of broad-spectrum digestive enzyme replacement therapy.